Cutaneous Leishmaniasis. Cutaneous Leishmaniasis
Conditions
Interventions
Intervention 1: Interalesional Glucantime injection, until the lesion with 1 mm of its surrounding is completely infiltrated, in size basis until the lesion is completely infiltrated and indurated, we
Treatment - Drugs
Interalesional Glucantime injection, until the lesion with 1 mm of its surrounding is completely infiltrated, in size basis until the lesion is completely infiltrated and indurated, weekly up to 8 wee
Topical TCA 50%, after the lesion is frosted, the lesion site without washing is covered with topical cream, weekly until improvement time and will repeat up to 8 weeks
Sponsors
Research Council of Mashhad University of Medical Sciences
Eligibility
Sex/Gender
All
Age
No minimum to 80 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: presence of cutaneous leishmaniasis in less than 6 months prior to the study that their disease has been approved by direct smear and stained with Giemsa or positive dermal biopsy, 3-month treatment-free interval from the last treatment course Exclusion criteria: pregnancy, breast-feeding, any administration of any other medication during the study that has anti-leishmaniasis ingredient during 2 last months, history of severe renal impairment, pulmonary and cardiovascular disease
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Complete healing. Timepoint: first time at 8th weeks after treatment and the second time in follow up visit after 3 months of commencement of the study. Method of measurement: Measuring the width and induration and ulcer size. | — |
Secondary
| Measure | Time frame |
|---|---|
| Side effects. Timepoint: at each follow up visit. Method of measurement: Physical examination. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactHasan Amir Soleimani
Research center for skin disease and cutaneous leishmaniasis
Outcome results
None listed